3 Biotech Stocks That Could Double in 2022
They're risky. But with the high risk comes the potential for high rewards.
Source: fool.com
Page 38 - Adicet Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Adicet Bio Today - Breaking & Trending Today
Early clinical data validate rare immune cell for Adicet's off-the-shelf cancer therapy
Adicet Bio makes its therapies from gamma delta T cells, a rare type of immune cell that the company believes offer advantages compared to other cell therapies. The company now has early Phase 1 data that bring some validation to the approach.
Source: medcitynews.com
Why Adicet Bio Stock Is Skyrocketing Today
The company reported positive interim results from a phase 1 study.
Source: fool.com
Chutes & Ladders—J&J science chief Stoffels the latest C-suite leader to retire
Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., will retire at the end of the year, following the lead of CEO Alex Gorsky, who also departs soon. Emile Nuwaysir led Bayer's $1 billion bet on Parkinson's disease, and now he heads up gene therapy biotech Ensoma. Genentech's early cancer research leader Shiva Malek jumps to Novartis' NIBR oncology unit.
Source: fiercebiotech.com
Global Cellular Immunotherapy Market research Report 2021: Companies are Focusing on Developing Off-the-Shelf Allogeneic Therapies for New and Improved Cancer Treatment
/PRNewswire/ -- The "Cellular Immunotherapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's...
Source: prnewswire.com